Physalin B
Catalog No: CFN92941
Physalin B shows antimalarial, anti-Trypanosoma cruzi, anti-bacterial, anti- leukemia activities, it has the potential to be developed as an effective chemotherapeutic lead compound for the treatment of malignant melanoma, it inhibits androgen-independent prostate cancer cell growth through activation of cell apoptosis and downregulation of androgen receptor expression. Physalin B exhibits a minimum inhibitory concentration value (MIC) against Mycobacterium tuberculosis H(37)Rv strain of 32 microg/mL. Physalin B also presents antinociceptive properties associated with central.
